The Current Ratio as of December 2024 (TTM) for Monte Rosa Therapeutics, Inc. (GLUE) is 6.03

According to Monte Rosa Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 6.03. This represents a change of 7.32% compared to the average of 5.62 of the last 4 quarters.

Monte Rosa Therapeutics, Inc. (GLUE) Historical Current Ratio (quarterly & annually)

How has GLUE Current Ratio performed in the past?

The mean historical Current Ratio of Monte Rosa Therapeutics, Inc. over the last ten years is 8.12. The current 6.03 Current Ratio has changed 7.33% with respect to the historical average. Over the past ten years (40 quarters), GLUE's Current Ratio was at its highest in in the June 2021 quarter at 33.20. The Current Ratio was at its lowest in in the March 2020 quarter at 0.

Monte Rosa Therapeutics, Inc. (GLUE) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Monte Rosa Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Monte Rosa Therapeutics, Inc. (GLUE) Average Current Ratio

How has GLUE Current Ratio performed in the past?

The current Current Ratio of Monte Rosa Therapeutics, Inc. (GLUE) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Monte Rosa Therapeutics, Inc. (GLUE) Current Ratio vs. Peers

How is GLUE’s Current Ratio compared to its peers?

Monte Rosa Therapeutics, Inc.’s Current Ratio is less than Nkarta, Inc. (12.91), less than Lyell Immunopharma, Inc. (13.43), less than Generation Bio Co. (6.34), greater than Sana Biotechnology, Inc. (4.47), less than Design Therapeutics, Inc. (34.61), less than Werewolf Therapeutics, Inc. (10.10), less than Ikena Oncology, Inc. (15.32), greater than Stoke Therapeutics, Inc. (5.09), greater than Foghorn Therapeutics Inc. (4.77), less than Shattuck Labs, Inc. (7.96), less than Kymera Therapeutics, Inc. (8.55), greater than Nurix Therapeutics, Inc. (5.28), less than Gracell Biotechnologies Inc. (7.73), less than Theseus Pharmaceuticals, Inc. (29.93), less than Erasca, Inc. (11.00),

Build a custom stock screener for Monte Rosa Therapeutics, Inc. (GLUE) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Monte Rosa Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Monte Rosa Therapeutics, Inc. (GLUE) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Monte Rosa Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.